<DOC>
	<DOCNO>NCT01706367</DOCNO>
	<brief_summary>This first-in-human study ( phase 1 ) 3-dose vaccination regimen one three dose level C difficile vaccine without adjuvant healthy adult age 50 85 year . The main goal study determine safe well-tolerated vaccine . In addition , study aim ass immune response C difficile vaccine .</brief_summary>
	<brief_title>Evaluation 3-dose Vaccination Regimen With One Three Ascending Dose Levels Clostridium Difficile Vaccine With Without Adjuvant Healthy Adults Aged 50 85 Years</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Evidence personally sign date informed consent document . 2 . Healthy male female adult age 50 85 year enrollment determine medical history , physical examination , clinical judgment investigator eligible study . Subjects preexist chronic medical condition determine stable may include . 3 . Male subject , opinion investigator , biologically capable father child , sexually active woman childbearing potential must agree use highly effective method contraception time informed consent least 28 day last dose investigational product ( Visit 9 Month 7 ) . 4 . Female subject childbearing potential ( ie , meet least one follow criterion ) : Have undergone hysterectomy bilateral oophorectomy ; Have medically confirm ovarian failure Are medically confirm postmenopausal 5 . Availability entire duration study , able comply schedule visit , treatment plan , laboratory test , study procedure include completion electronic diary ( eDiary ) Day 1 Day 7 follow vaccination . 6 . Ability contact telephone study participation . 1 . Previous administration investigational C. difficile vaccine C. difficile monoclonal antibody therapy . 2 . Proven suspect prior episode CDAD . 3 . Unstable chronic medical condition disease require significant change therapy hospitalization worsen disease within 12 week receipt study vaccine . 4 . Serious chronic medical disorder include metastatic malignancy , severe chronic obstructive pulmonary disease ( COPD ) , end stage renal disease without dialysis , clinically unstable cardiac disease , disorder investigator 's opinion precludes subject participate study . 5 . Donation blood volume 250 mL great , donation plasma within 3 month prior enrollment conduct study . 6 . Bleeding diathesis condition associate prolonged bleeding time may contraindicate intramuscular injection blood draw include subject take anticoagulant , antiplatelet and/or antithrombotic agent except low dose daily aspirin ( â‰¤325mg per day ) within 30 day enrollment completion Visit 9 ( Month 7 ) . 7 . Any contraindication vaccination vaccine component . 8 . `` Immunocompromised person subject currently immunosuppressive therapy history immunosuppressive therapy , include chemotherapy agent treatment diseases include , limited cancer , inflammatory bowel disease autoimmune disease . Recent history ( within past 6 month ) long term ( 7 day longer ) systemic corticosteroid use . '' 9 . Subjects receive oral parenteral antibiotic within 1 month enrollment . Topical antibiotic allow . 10 . Receipt blood product immunoglobulin ( include monoclonal antibody ) within 6 month enrollment conclusion study . 11 . Participation investigational interventional study within 30 day current study begin and/or study participation . Participation purely observational study acceptable . 12 . Subjects investigational site staff member relatives site staff member , subject Pfizer employee directly involve conduct trial . 13 . Females childbearing potential ; male childbearing potential use highly effective contraception agree continue highly effective contraception least 28 day last dose investigational product ( Visit 9 Month 7 ) . 14 . Females receive exogenous estrogen therapy . 15 . Residence nursing home , longterm care facility , requirement semiskilled nursing care assist living . An ambulatory subject live autonomous manner retirement home village eligible trial . 16 . Any abnormality screen hematology and/or blood chemistry laboratory value accord toxicity grade scale . Subjects stable Grade 1 abnormality hemoglobin , leukocyte count , platelet may consider eligible discretion investigator . 17 . A positive screening test know infection human immunodeficiency virus ( HIV ) , hepatitis B virus ( HBV ) and/or hepatitis C virus ( HCV ) . 18 . Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation investigational product administration may interfere interpretation study result , judgment investigator , would make subject inappropriate entry study .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Clostridium difficile</keyword>
	<keyword>vaccine</keyword>
</DOC>